Keros Therapeutics, Inc. (KROS) Cash Flow Statement
Keros Therapeutics, Inc. (KROS) generated -$48.0M of operating cash flow over the twelve months to 2026-06-30, spent $494000 on capital expenditure and had free cash flow of -$48.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KROSKeros Therapeutics, Inc.Follow KROS — free
—
Price chart with a free account
- Market cap
- 223.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -62.1 | -124.5 | -160.9 | 107.5 | -48.0 | |
| Capital expenditure | 1.0 | 2.5 | 1.9 | 1.6 | -0.5 | |
| Free cash flow | -63.2 | -127.0 | -162.8 | 106.0 | -48.5 | |
| Share repurchases | — | — | 0.0 | 375.0 | — | |
| Stock-based compensation | 11.7 | 28.8 | 34.9 | 28.7 | — |
USD millions · SEC XBRL
Keros Therapeutics, Inc. — questions
- What is Keros Therapeutics, Inc.'s operating cash flow?
- -$48.0M over the twelve months to 2026-06-30.
- How much does Keros Therapeutics, Inc. spend on capital expenditure?
- $494000 over the twelve months to 2026-06-30.
- What is Keros Therapeutics, Inc.'s free cash flow?
- -$48.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Keros Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.